Posts
- US Tax Reform Jump-Starts M&A Activity in 2018
- Is Diversification the Right Strategy for Big Pharma?
- Biopharma companies have the cash and are ready to deal
- Biosimilar Boon for Europe’s Payers as Humira Price Falls
- Orphan Assets Still Hot as Pricing Debate Rages
- Movember: Prostate cancer, largely controllable, still kills; increasing prevalence driving drug development
- In respiratory diseases, it is all about delivery
- Will Trump Succeed in Curbing Drug Prices in 2019?
- Bayer Cuts Internal R&D, Looking Outside
- The diabetes battle: Will Novo’s oral GLP-1 knock Trulicity off its perch?
- GSK buys Tesaro to re-enter oncology race
- Rare and Innovative? Not Enough for European Payers
- As Keytruda expands, payers recoil
- Gene therapy ‘cures’ force new payment models
- ‘Tis the Season to be Vaccinated
- 2019: The Year of the Digital Pharma?
- Is January’s M&A a flash in the pan, or does it signal sustained dealmaking heat
- New Pharma Models for a new Healthcare Era
- Cervical cancer is under attack from multiple modalities – including AI
- Immuno-Oncology: Still the hottest game in town
- Cancer Awareness Day : Cost Matters
- As Rare Disease Drugs Multiply, So Must Creative Ways to Pay for Them
- Better late than never: targeted therapies reach ovarian cancer
- Genes may trump hormones in treating endometriosis
- Sniffing out Parkinson’s Disease
- New treatments – and maybe a cure – for hemophilia
- Cannabis-based Epidiolex helps some epilepsy sufferers
- A Big R&D Challenge
- Cervical cancer screening comes to your mobile phone
- Could the gut microbiome help manage diabetes?
- Hepatitis drugs are effective and ever-cheaper. Yet the disease still kills.
- NASH: The silent killer
- Big Pharma’s Psoriasis Battleground
- Tackling hypertension
- From Herceptin to Rozlytrek: how cancer drugs are getting more personalized
- Immunotherapies battle for lead in lung cancer
- HIV Therapy: Safer, simpler and longer-lasting
- The Big 2020 Challenge
- More Options for Ovarian cancer
- Coronavirus: A catalyst for digital health?
Pages
- Shop
- Cart
- Checkout
- My Account
- Home
- Terms and Conditions
- Privacy Policy
- Contact us
- Cookie Policy
- Special Offer
- Special offers
- Sanofi Login Screen
- Benign Prostatic Hyperplasia and Prostatitis Device-Based Treatments Market
- Pain Management Devices Market
- Global Diabetes Management Devices Market
- Thank-You
- Pharma Externalization Strategies 2016
- Global Market for Arthroscopy and Sports Medicine Devices
- Cystic Fibrosis: Report Singles
- Head and Neck Cancer: Report Singles
- Crohn’s Disease: Report Singles
- About Us
- Blogs
- Buy any 5 reports and only pay for 3!
- Neuropathic Pain: Report Singles
- Diabetes Singles
- Diabetes Report Store Landing
- Gene Therapy Reports
- Influenza
- Discounts
- Cervical Cancer Awareness Week – 21 – 27 January 2019
- Pharma Report Store
- World Cancer Day 2019
- Rare Disease Day 2019
- Market Spotlight – Report Special Offers
- Alexa Terms and Conditions
- March 2019 is World Endometriosis Awareness Month
- Ovarian Cancer Awareness Month 2019
- World Parkinson’s Awareness Day 2019
- World Hemophilia Day 2019
- It’s World Meningitis Day – 24 April
- May 10 is World Lupus Day
- World Epilepsy Week, May 20-26 2019
- 20% off selected Datamonitor Healthcare Market Spotlight Reports
- Cervical Cancer Awareness Week 2019
- Diabetes Awareness Week 10 – 16 June
- World Hepatitis Day – July 28 2019
- Sitemap
- Thank you for submitting your request
- It’s Psoriasis Awareness Month August 2019
- Vascular Awareness Month September 2019
- MedTech Reports
- Breast Cancer Awareness Month
- World Osteoporosis Day 2019
- Gene Therapy Awareness Month
- November 2019 is Lung Cancer Awareness Month.
- Prostate Cancer/ Movember campaign
- December: HIV Awareness campaign
- Black Friday 2019
- Festive Period Promotion
- Disease Analysis Reports
- Refund policy
- Lung Cancer Awareness Month
- Black Friday 2020
- Festive Period Promotion
Products
- France, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- Germany, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- Italy, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure
- Germany, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure
- Italy, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- Spain, Neurological Market Opportunities: Disease Incidence and Prevalence, And Surgical Procedure Volumes
- United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- United States, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- United States, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes
- U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators
- Current and Emerging U.S. Markets for Myocardial Revascularization, Repair, and Regeneration Products and Therapies
- U.S. Markets for Diagnostic Oncology-Related X-Ray-Based Imaging Products
- U.S. Markets for Compression Therapy and Pressure Reduction and Relief Products Used for Wound Management
- U.S. Benign Uterine Conditions Therapy Systems Market
- U.S. Markets for Orthopedic Biomaterials for Bone Repair and Regeneration
- European Markets for Prosthetic Vascular Grafts
- U.S. Markets for Orthopedic Biomaterials for Viscosupplementation and Cartilage, Ligament/Tendon, and Meniscal Repair and Regeneration
- France, Surgical Procedure Volumes
- Women’s Health: Trends and Opportunities in the U.S. Osteoporosis Management Market
- Women’s Health: U.S. Markets for Reproductive Management Products
- Germany, Surgical Procedure Volumes
- U.S. Markets, Trends, and Opportunities in Patient Monitoring Products
- Spain, Surgical Procedure Volumes
- Psychiatry KOL Insight Interview
- Selexipag for Pulmonary Arterial Hypertension
- Palbociclib for Breast Cancer
- NASH KOL Insight Interview #1
- Macitenan for Pulmonary Arterial Hypertension
- NASH KOL Insight Interview #2
- Seizure Pulse Survey
- Aromatase Resistance and Palbociclib for Breast Cancer
- U.S. Ophthalmic Surgical Systems Market, April 2014
- Congestive Heart Failure Pulse Survey
- Midostaurin
- Volasertib
- Breast Cancer Pulse Survey
- Post-EASL KOL Insight Interview
- Ovarian Cancer Pulse Survey
- Breast Cancer KOL Insight Interview
- Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey
- Flolan
- Dyslipidemia KOL Insight Interview #1
- Dyslipidemia KOL Insight Interview #2
- Post-AAIC KOL Interview
- SGLT-2 Pulse Survey
- GLP-1 Pulse Survey
- Aplidin
- Vibativ
- Sivextro
- Dalvance
- Delafloxacin
- Orbactiv
- Cubicin
- Inpatient Infections Pulse
- Zelapar
- Retinal Disorders (AMD and DME) Pulse
- Multiple Sclerosis KOL Insight Interview
- 2014 October Dermatology Survey
- Dermatology KOL Interview
- Ebola KOL Interview #1
- U.S. Disease Incidence and Prevalence
- Ebola KOL Interview #3
- Post-AASLD US KOL Interview
- 2014 Community-Acquired Pneumonia Pulse
- 2015 Chronic Lymphocytic Leukemia (CLL) Pulse
- 2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview
- U.S. Markets for Anesthesia and Ventilation Products, February 2015
- U.S. Markets for Cardiac Rhythm Management Products, February 2015
- Neuromodulation KOL Interview
- Kadcyla
- Neratinib
- Tykerb
- Post-CHDI Huntington’s Disease KOL Interview
- ADPD Alzheimer’s Disease Pulse
- Sarilumab
- Sirukumab
- Actemra
- Pediatric Acute Leukemias (AML/ALL) KOL Interview
- Post-ADPD Alzheimer’s Disease KOL Interview
- MDS/AML KOL Interview
- Breakthrough Therapy Designation: Paving the Way for Innovation
- Delzicol/Asacol HD
- 2015 Breast Cancer Pulse #1
- Tenofovir alafenamide fumarate
- 2015 Breast Cancer Pulse #2
- Post-EASL KOL Interview
- 2015 Breast Cancer Pulse #3
- Ketek
- Tygacil
- solithromycin
- Spectracef
- Beraprost 314d
- Zeftera
- Zyvox
- Factive
- Invanz
- omadacycline
- Accountable Care Organizations – What Impact on Pharma
- Oncology Pathways in the US – Friend or Foe for Pharma
- Biosimilars and Reimbursement KOL Interview
- 2015 Post-AAIC KOL Interview
- Dyslipidemia and Diabetes Reimbursement KOL Interview:
- 2015 Cancer Drug Pricing Surveys
- 2015 PCSK9 Inhibitors Pulse
- Asia-Pacific: Surgical Procedure Volumes
- U.S. Markets for Orthopedic Extremity and Soft Tissue Repair, September 2015
- Venetoclax
- Ganetespib
- ProstAtak
- Malignant Melanoma Pricing, Reimbursement and Access
- Alzheimer’s KOL Interview
- Biosimilars Market Access in the US
- ChimeriVax-Dengue
- Vigil
- Recentin
- 2015 Jardiance EMPA-REG CVOT Pulse
- U.S. Surgical Procedure Volumes
- U.S. Patient Monitoring Devices Market, November 2015
- Treatment of VTE – US KOL Interview
- Treatment of VTE – EU KOL Interview
- U.S. Markets for Minimally Invasive Benign Prostatic Hyperplasia and Prostatitis Therapies
- Global Spinal Implants Market
- U.S. Markets for Drug and Fluid Delivery Devices
- Tybost
- D/C/F/TAF
- F/TAF
- Tivantinib
- Peretinoin
- Asia-Pacific Disease Incidence and Prevalence
- Special Report: The Intersection Between Tech and Pharma (Part 1. Google)
- Intersection Between Tech and Pharma KOL Interview
- The Intersection Between Tech and Pharma Special Report (Part 2. Apple)
- OTC Distribution in Europe – The New Global Agenda
- Zaltrap
- The Intersection Between Tech and Pharma Special Report (Part 3. Intel, Samsung, IBM, and GE)
- Ampyra
- Key Trends in European Market Access
- Drug Pricing and Market Access KOL Interview
- VLP QIV
- MF-59 adjuvanted QIV
- Faslodex
- Follicular Lymphoma KOL Interview
- Ibrance
- Ixempra
- Alpelisib
- Taselisib
- Entinostat
- AGS-003
- Cometriq
- Triple Negative Breast Cancer KOL Interview
- Acute Lymphocytic Leukemia KOL Interview
- Datamonitor Schizophrenia KOL Interview
- Datamonitor Big Pharma Licensing Trends
- Datamonitor Schizophrenia KOL Interview 2
- Asthma and COPD KOL Interview
- Global Radiation Therapy Systems Market, March 2016
- CSL627
- Bax 817
- Ularitide
- Reasanz
- Herceptin
- U.S. Markets for Interventional Cardiology Products, April 2016
- Visudyne
- U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management
- blisibimod
- Macugen
- Fovista
- PT003
- CHF 5993
- FF/UMEC/VI
- Ultibro
- Toca 511/FC
- DCVax-L
- ICT-107
- VB-111
- Temodar
- Angiomax
- Effient
- Zontivity
- Kengreal
- Brilinta
- Pyridorin
- Glembatumumab Vedotin
- Sofosbuvir/Velpatasvir/GS-9857
- Sofosbuvir/Velpatasvir
- Buparlisibi
- Brintellix
- Biomedtracker Entresto Pulse
- Lebrikizumab
- Biomedtracker Diabetic Nephropathy/Diabetic Kidney Disease KOL Interview
- 2016 Biomedtracker Post-EASL Hepatitis C Survey
- Global Neurostimulation Devices Market, June 2016
- Wearables are Transforming R&D and Care Delivery
- Briviacti
- 2016 Biomedtracker ASCO Survey
- U.S. Markets for Respiratory Care Products, June 2016
- U.S. Markets for Respiratory Care Products
- Semaglutide (Injectable)
- Semaglutide (Oral)
- LixiLan
- International Markets for Vascular Access Site Closure Devices — June 2016
- Bococizumab
- International Markets for Vascular Access Site Closure Devices
- Potiga
- MEDI-7510
- Datamonitor Meningococcal Vaccines KOL Interview
- Perjeta
- Nimotuzumab
- GS-5745
- Coumadin
- Lovenox
- Vasotec
- Betrixaban
- Tildrakizumab
- Acute Myelogenous Leukemia (AML) KOL Interview
- Brexit and the life sciences: What lies ahead?
- Dovonex
- ABBV-066
- Silkis/Vectical
- Sorilux
- Pneumococcal Vaccines KOL Interview
- Dovobet
- Tagrisso
- Vargatef
- Namenda
- Azeliragon
- Idalopirdine
- Verubecestat
- LMTX
- Aricept
- Razadyne
- RVT-101
- Exelon
- Gantenerumab
- Solanezumab
- 2016 M&A Analysis
- US Neurointerventional Devices Market, September 2016
- US Neurointerventional Devices Market
- U.S. Markets for Advanced Wound Care Products
- U.S. Markets for Stroke Management
- The Global Molecular Diagnostics Market
- U.S. Markets for Obesity Drugs & Devices
- U.S. Markets for Critical Care Patient Management Products
- U.S. Neurostimulation Devices Market, June 2015
- U.S. Markets for Sports Medicine Products
- U.S. Markets for Orthopedic Biologic and Tissue Engineered Products
- U.S. Markets for Neurosurgical and Neurointerventional Products
- U.S. Markets for Specialty Endoscopic Surgery Products
- U.S. Markets for Biologic and Tissue Engineered Devices – Cardiovascular and Neurological Products
- U.S. Markets for Heart Valve Disorder Management Products
- European Markets for Spinal Motion-Preserving Devices
- Women’s Health: U.S. Markets for Female Urinary Incontinence Therapies
- U.S. Cancer Statistics Update 2014
- U.S. Markets for Interventional Peripheral Vascular Disease Management Products and Technologies
- U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging
- U.S. Markets for Invasive and Noninvasive Diagnostic Cardiology Products
- U.S. Markets for General and Pelvic Endoscopic Surgery Products
- France, Disease Incidence and Prevalence
- U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening
- United Kingdom, Surgical Procedure Volumes
- Mid Pharma Outlook
- 2016 M&A Outlook
- 2014 M&A Update
- Q2 2016 Earnings Previews
- Orphan Drug Market Outlook to 2017
- Big Pharma Outlook 2015
- Japan Pharma Outlook
- Teflaro
- Aducanumab
- Global Markets for Orthobiologics for the Repair and Regeneration of Bone
- baricitinib
- Global Markets for Infection Control and Biosafety Products, October 2016
- Big Pharma Licensing Trends, 2011–15
- Immuno-Oncology Deal Trends, 2011–15
- Trends in Gene Therapy
- Precision Medicine and the Future of Healthcare
- CER, HEOR, and Value-Based Frameworks in the US
- Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue
- R&D Trends 2016
- Psoriatic Arthritis: Market Access Pricing & Reimbursement
- Chronic Obstructive Pulmonary Disease (COPD): Market Access Pricing & Reimbursement
- Asthma Pricing, Reimbursement, and Access
- Pharma’s Patient Centricity
- Key Trends in BRICMIST Market Access
- US Image-Guided Surgical Neuronavigation and EBRT Systems Market
- Profitability Assessment of Branded Generic Inhalers
- Breast Cancer Pulse #2
- Breast Cancer Pulse #1
- Actelion
- Turkey Regulatory Issues
- India Regulatory Issues
- The Evolution of Pharmaceutical Sales Strategies Continues
- Indonesia Regulatory Issues
- Indonesia Healthcare System Overview
- Germany Regulatory Issues
- US Pricing and Reimbursement
- Germany Pricing and Reimbursement
- France Regulatory Issues
- US Regulatory Issues
- Japan Regulatory Issues
- Germany Healthcare System Overview
- France Healthcare System Overview
- UK Regulatory Issues
- US Healthcare System Overview
- Access in Emerging Markets: HTA is Making Inroads
- Argentina Regulatory Issues
- UK Healthcare System Overview
- Spain Healthcare System and Drug Regulatory Analysis
- India Pharmaceutical Market Dynamics
- EGA Biosimilars Conference 2015
- UK Generics and Biosimilars
- Beyond-the-Pill Services and Solutions: Pharma’s Next Frontier?
- Russia Pharmaceutical Market Dynamics
- Indonesia Pharmaceutical Market Dynamics
- Germany Generics and Biosimilars
- Indonesia Generics and Biosimilars
- France Generics and Biosimilars
- Russia Generics and Biosimilars
- Argentina Healthcare System Overview
- Contract Research Organizations: Health and Wealth in 2013
- CRO Snapshot 2013
- An Evolution in Partnering: Can CROs Lead the Way in Innovation?
- CRO Snapshot: Clinical Outsourcing in 2012
- Disruptive Innovation and the Pharmaceutical Contract Services Sector
- CMOs in China and India: Still the Places to be?
- CMO Market Dynamics and Strategies
- Leading Players in the CMO Market
- The Contract Biomanufacturing Market Outlook to 2017
- CRO League Tables: Acquisition, Competition, and Privatization
- Surviving a Scandal: How to Expect the Unexpected
- China Regulatory Update
- Generics: Regulatory Update
- Value-Based Pricing – Evolution Rather Than Revolution
- HER2+ Breast Cancer Pricing and Reimbursement
- Managed Entry Agreements
- Poland Pricing and Reimbursement
- Japan Pricing and Reimbursement
- Orphan Drug Pricing and Reimbursement
- Turkey Pricing and Reimbursement
- India Pricing and Reimbursement
- US Specialty Drug Market Access
- Global Markets for Hospital-Based Point-of-Care Diagnostic Products
- Global Markets for Non-Hospital-Based Point-of-Care Diagnostic Products
- Abemaciclib
- Q4 2016 Outlook Report
- Biopharma Quarterly Dealmaking Statistics, Q3 2016
- Pacts in Medtech
- Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 1
- Biosimilars Portfolio and Pipeline Trends, 2016
- Data in Healthcare: Underpinning the Shift to Value
- Acne Prescribing Practices Pulse Survey
- Tyvaso for Pulmonary Arterial Hypertension
- Pressures and Opportunities in Pain
- Product Launch and Commercialization Strategies
- 2016 Post-AHA Report
- Datamonitor Psoriatic Arthritis KOL Interviews
- Advanced Wound Care Products Market
- Women’s Health: Osteoporosis Diagnostic Products
- Non-Small Cell Lung Cancer KOL Interview
- Women’s Health: Market for Minimally Invasive Female Urinary Incontinence Devices
- Implantable Cardiac Rhythm Management Device Markets, December 2016
- Big Pharma Outlook 2025
- PCSK9 Inhibitors Pricing Reimbursement and Access
- Surgical Procedure Volumes, US
- PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report
- Mail Order and Internet Pharmacy in Europe
- Hemophilia Pricing, Reimbursement, and Access
- Social Media in Pharma
- Mid Pharma Licensing and M&A Trends, 2011–16
- Biosimilars Market Access in Psoriatic Arthritis
- Biosimilars Market Access in Psoriasis
- Big Pharma Licensing Trends, 2012–16
- Abuse-Deterrent Opioids Survey KOL Interview
- Chronic Neuropathic Pain KOL Survey
- Opioids and Chronic Neuropathic Pain Management KOL Interview
- Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey
- Datamonitor Axial Spondyloarthritis KOL Interviews
- Non-Alcoholic Steatohepatitis (NASH) Survey
- Chronic Migraine Survey
- Biosimilars Market Access in the U.S.
- Pharma Intelligence Report Store Article Collection Innovation, Data and Machine Learning Report 2
- Spravato
- Global Diabetes Management Devices Market
- Global Market for Arthroscopy and Sports Medicine Devices
- Q2 2017 Meddevicetracker Outlook Report
- Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 1
- Datapack – Pharmaprojects Pharma R&D Annual Review 2017
- Datamonitor Healthcare Crohn’s Disease KOL Interviews
- Immuno-Oncology Deal Trends, 2012–16
- Biosimilars in Emerging Markets
- Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
- Pharma Intelligence Report Store Article Collection Digital Patient Management
- 2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ACC Report
- Transforming Pharmaceutical R&D with Data
- Biopsy Devices Market
- LT-02
- NOACs Pricing, Reimbursement, and Access
- Pharma Intelligence Report Store Article: Collection Cybersecurity
- Onfi
- Aptiom
- Lyrica
- Epidiolex
- Keppra
- Banzel
- Fycompa
- Ganaxolone
- Pain Management Devices Market
- From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?
- General and Pelvic Endoscopic Surgery Devices Market
- Biosimilar Insulin Market Access
- Crenezumab
- Integrated Delivery Networks in the US
- Big Pharma Outlook 2026
- Heart Valve Repair and Replacement Devices Market
- Erdafitinib
- Drug Pricing in the US
- Quizartinib
- Rydapt
- IDHIFA
- Iomab-B
- Ivosidenib
- Zeltherva
- Gilteritinib
- Vyxeos
- Oral Vidaza
- ATIR101
- Idasanutlin
- Victoza
- The Growing Impact of Real-World Evidence
- Inhalation Drug Delivery Devices Market
- Orthobiologics Market for Musculoskeletal Soft Tissue Replacement and Regeneration
- Pharma Intelligence Report Store Article Collection Digital Policy & Regulation Report 2
- Regenerative Medicine Landscape
- Pharma-Payer Partnerships in Emerging Markets
- Minimally Invasive Weight Loss (Bariatric) Devices Market
- Diagnostic and Guided Interventional Cardiology Products Market
- Biomedtracker Q3 2017 Outlook Report
- Trends in CNS Dealmaking, 2012–16
- Zejula
- Zybrestat
- Mirvetuximab Soravtansine
- Farletuzumab
- Zepsyre
- Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews
- Datamonitor Healthcare Ulcerative Colitis KOL Interviews
- Specialty Endoscopic Surgery Devices Market
- Dupilumab
- Gene Editing: The Next Breakthrough in Regenerative Medicine
- Leukemia KOL Insight and Pulse Survey Bundle
- Squalamine
- Tezacaftor/Ivacaftor
- Colobreathe
- 2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ESC Report
- Elocon
- Q4 2017 Meddevicetracker Outlook Report
- Biomedtracker Q4 2017 Outlook Report
- Clinical Trial Strategies in Biosimilar Drug Development
- Xeljanz
- Siliq
- Orencia
- Tremfya
- Viekira Pak franchise
- Daklinza
- Harvoni
- Epclusa
- Zepatier
- Ximency
- Mavyret
- Vosevi
- Sovaldi
- Zafatek
- Tenelia
- Nesina
- Lusefi
- Apleway
- SaxaDapa
- Toujeo
- Suglat
- Afrezza
- Tradjenta
- Onglyza
- Tresiba
- Trulicity
- Xultophy
- ITCA 650
- Lantus
- Levemir
- Byetta
- Lyxumia
- Januvia
- Marizev
- Ertugliflozin
- Ryzodeg
- Bydureon
- Galvus
- Glyxambi
- Sotagliflozin
- Plegridy
- Aubagio
- Ponesimod
- Avonex
- Tecfidera
- Lemtrada
- Zinbryta
- Rebif
- Betaseron
- Gilenya
- Catch Up On CAR-T
- Mavenclad
- Ocrevus
- ALKS 8700
- Ofatumumab
- Copaxone
- Siponimod
- Angioplasty Catheters Market
- Telehealth, Wearables and Apps – Report 1
- Telehealth, Wearables and Apps – Report 2
- Telehealth, Wearables and Apps – Report 3
- Multikine
- GSK Woes Raise Big Pharma R&D Question
- 5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures
- Synribo
- Tasigna
- Iclusig
- European Surgical Procedure Volumes: Orthopedic and Spine Procedures
- Bosulif
- Gleevec
- Asciminib
- Sprycel
- Datamonitor Healthcare Strategy: Gene Therapy Pipeline and Portfolio Analysis
- Napabucasin
- Vericiguat
- Omecamtiv Mecarbil
- OncoVAX
- TS-1
- Lonsurf
- Vectibix
- Entresto
- Erbitux
- MPC-150-IM
- C-Cure
- lefitolimod
- Corlanor
- European Surgical Procedure Volumes: Breast, general, gynecologic, organ transplant, neurosurgical, ophthalmalogic, and urologic
- Immuno-Oncology Overview
- Acute Myeloid Leukemia Pricing, Reimbursement, and Access
- Pulse Oximetry Devices Market
- Dengvaxia
- TAK-003
- TetraVax-DV
- V180
- Dengue DNA vaccine
- DPIV
- JP Morgan Healthcare Conference Preview
- NeoRecormon
- Injectafer
- Feraheme
- Dexferrum
- Auryxia
- Aranesp
- Roxadustat
- Venofer
- Epogen
- Feraccru
- Mircera
- Orphan Drug Access and Pricing in Emerging Markets
- Jevtana
- Provenge
- JP Morgan Healthcare Conference Review
- Xofigo
- Xtandi
- Zytiga
- DCVAC/PCa
- Darolutamide
- Apalutamide
- Rubraca
- Relugolix
- Yonsa
- Eligard
- Firmagon
- Trelstar
- Zoladex
- Lupron
- Biosimilars Market Access in the EU
- Bevyxxa
- Interventional Cardiology Vascular Stents
- Latest Trends in Orphan Drug Pricing and Reimbursement
- Atrasentan
- Behind The Scenes Of Digital Health: Medtech Players And Partners
- Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s
- Engaging Patients and Navigating Laws: What To Consider When Developing Health Apps
- Game On For Akili’s Cognitive Control Tech
- Acorda Company Analysis
- Gene Therapy Deal-Making Trends, 2012–17
- Philips To Create More Context, Connectedness And Continuity And Shift Sick Care To Health Care
- Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym
- Technology Gap Separates OTC Drug Firms From SelfCare Sales Growth
- Telehealth Reforms Praised At Senate Hearing
- Dupixent
- Fasenra
- Xolair
- QVM149
- Dulera
- Cinqair
- Flutiform
- Singulair
- GE Healthcare’s New Value Proposition: The Strategic Language Of Software
- Spinal Fusion Implanted Instrumentation Market
- Big Pharma Diversification Strategies
- Ovarian Cancer Pricing, Reimbursement, and Access
- Prolia
- Tymlos
- Evenity
- Forteo
- Pradaxa
- Xarelto
- Eliquis
- Savaysa
- Crohn’s Disease and Ulcerative Colitis Pricing, Reimbursement, and Access
- Aristada
- Invega Sustenna/Invega Trinza
- Lonasen
- MIN-101
- Nuplazid
- Lu AF35700
- Vraylar
- Drug Delivery: Infusion Devices
- Interventional Cardiology: Atherectomy and Thromboembolectomy
- State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View
- CEO-To-Worker Pay Ratios Averaged 150-1 At Six Top Medtech Companies In 2017
- ALKS 3831
- Zyprexa
- Lumateperone
- Lamictal and Lamictal XR
- Risperdal Consta
- Saphris
- Geodon
- State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View
- Chronic Heart Failure Pricing, Reimbursement, and Access
- M&A Outlook 2018
- M&A Analysis 2018
- Spinal Motion Preservation Devices
- Spinal Cord Stimulation Devices Market
- AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement
- GSK’s Head Of Artificial Intelligence Unveils R&D Goals
- US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?
- Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It
- Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone
- NovoEight
- Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 ‘In The Coming Years,’ Official Says
- NovoSeven
- Alprolix
- Bay 94-9027
- Xyntha
- Idelvion
- LR769
- Eloctate
- Rixubis
- Advate
- Adynovate
- Kogenate
- Vonvendi
- BeneFix
- FEIBA
- Nuwiq
- Afstyla
- AMT-061
- Fitusiran
- SPK-8011
- SPK-9001
- Kovaltry
- N8-GP
- Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action
- You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments
- A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
- US FDA Commissioner: Agency Will Propose New Rule That Blends Quality System Regulation, ISO 13485
- Pfizer’s Reference Point on Trial Innovation : Ask the Patient
- Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
- Takeda/Shire Merger: Five Things To Worry About
- Estee Lauder Is Revising Claims, Retesting Products After Internal Breakdown
- Cosentyx
- Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights
- Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights
- Immuno-Oncology: What To Watch At ASCO 2018
- Taltz
- Otezla
- Enbrel
- Simponi
- Valoctocogene Roxaparvovec
- Hemlibra
- Rebinyn
- ‘Something’s Going To Happen’: Former FDAer John Bailey On Cosmetics Reform Legislation
- Yervoy
- Masitinib
- Imlygic
- Encorafenib
- Zelboraf
- Binimetinibi
- Daromun
- PDR001
- Seviprotimut-L
- IMO-2125
- Cotellic
- UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch
- Infographic – 2018 Pharma Pipeline Snapshot
- Petition Suggests Environmental Laws Compel FDA To Ban Oxybenzone, Octinoxate In Sunscreens
- FDA investigator insights: Device makers forget about the humans who use their products
- Cebranopadol
- Donaperminogene Seltoplasmid
- Gralise
- Lidoderm
- Mirogabalin
- Nucynta
- Raxatrigine
- Prostate Cancer: Market Access Pricing & Reimbursement
- Sunshine rules in the EU: Implications of a piecemeal approach
- Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
- Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
- Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
- ASCO 2018: Optimism As Industry Resets And Looks To What Is Next
- Regulatory headaches: Brexit’s not the only thing you need to worry about
- Novartis’ New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands
- Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss
- Diagnostic Electrocardiograph Products
- EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses
- Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology
- Cosmetic Preservatives Crisis Creeping Into CIR Program
- Paying For Gene Therapy: Will Pharma Be First In Line?
- New Reasons Not To Use EU MDR’s Four-Year Extension, But Comply Earlier Or Retire Products Instead
- Innovation in Deal-Making
- Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice
- Bayer’s US Playbook: The Smart Way To Top-Line Growth
- Oncology: Surgical Ablation Devices Market
- Pharma’s New R&D Models: Federating Innovation
- Neupro
- Nouriast
- Stalevo
- Xadago
- The Blockbusters No One Talks About
- Duopa
- Rytary
- Azilect
- Gocovri
- ND0612
- APL-130277
- Inbrija
- Ongentys
- Lovaza
- Zetia Franchise
- Lipitor
- Kynamro
- Crestor
- It’s Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims
- Thinking about using CMMI? Here are tips from the experts
- J&J Scores Early In ‘Hypoallergenic’ Case; Plaintiff’s Definition ‘Implausible,’ Court Says
- Plavix
- Aspirin
- Japan Pharma Outlook 2027
- Activase
- Aggrenox
- Under the Radar Takeover Targets
- NASH: Flying The Plane While Building It
- Nucala
- Stiolto Respimat
- Seebri Neohaler
- Striverdi Respimat
- Daliresp
- Symbicort
- Advair
- Duaklir Pressair
- Cimzia
- Anoro
- Tudorza Pressair
- Bevespi Aerosphere
- Tysabri
- PT010
- Incruse
- Arcapta
- Filgotinib
- Trelegy Ellipta
- Breo Ellipta
- Joint Replacement Implants
- Revefenacin
- Trimbow
- Utibron Neohaler
- Spiriva
- Stelara
- Entyvio
- Etrolizumab
- Humira
- Ozanimod
- Remicade
- Risankizumab
- Alofisel
- Upadacitinib
- Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?
- Key Questions in Immuno-Oncology
- Ninlaro
- Darzalex
- Pomalyst
- Empliciti
- Velcade
- Thalomid
- Farydak
- Oncology: Liquid Biopsy Products
- bb2121
- Isatuximab
- Ygalo
- Kyprolis
- Digital Pharma: Are We Nearly There?
- Renal Cell Cancer Pricing, Reimbursement, and Access
- Value-Based Reimbursement in the US
- Moving Medical Affairs To The Pharma Forefront
- Alecensa
- Tafinlar
- Xalkori
- Alimta
- Tarceva
- Capmatinib
- Cemiplimab
- Portrazza
- Entrectinib
- Lorlatinib
- Seribantumab
- Iressa
- Zykadia
- Dacomitinib
- Mekinist
- Ensartinib
- Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US
- Non-Small Cell Lung Cancer KOL Interview – NH, US
- Gilotrif
- Shire Company Analysis
- Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market
- Tobi/Tobi Podhaler
- Pulmozyme
- Orkambi
- Arikayce
- Vertex triple combinations
- Quinsair
- Kalydeco
- Cayston
- Bronchitol
- Symdeko
- Alunbrig
- Molecular In Vitro Diagnostic and Screening Tests for Oncology
- Bladder Cancer Pricing, Reimbursement, and Access
- CMS Actively Looking For New Reimbursement Pathway For Innovative Devices
- What Do Cosmetics Reform Campaigners Dream Of At Night? Rep. Schakowsky Just Reintroduced It
- Adaptive Clinical Trial Designs: US FDA Provides Checklist To Begin Study
- The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)
- Takeda To Press On With Core R&D Strategy Post-Shire
- Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1
- Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2
- Synagis
- Live-attenuated RSV vaccines
- Ad26.RSV.preF
- RSV preF vaccine
- RSV F Vaccine
- Cell And Gene Therapies Test New Waters In Pricing And Reimbursement
- MEDI8897
- ChAd155-RSV
- GSK-3003891A
- MVA-BN RSV
- Celgene
- Kinenza
- MOR208
- polatuzumab vedotin
- Selinexor
- Blincyto
- DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future
- Allergan
- Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
- Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
- Datamonitor Healthcare Type 2 Diabetes KOL Interview – US
- Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK
- Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy
- What Should You Be Earning? Salary Benchmarks And Hiring Trends In Regulatory Affairs
- Nail Polishes Contain Undeclared DEHP, Among Other ‘Regrettable Substitutions’ – Study
- As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability
- European Commission Sheds Light On MDR/IVDR Progress In Vital Update
- Eight Things To Know From Novartis’ Third Quarter Call
- FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE
- Orenitram
- Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened – As Have These Other Shocking Tales Of Irregular FDA Inspections
- Part B Payment Model Indexing Commercial Discounts Proposed By Genentech
- Real-World Evidence: US FDA’s Prucalopride Review Shows Datasets’ Utility And Limitations
- Two EU Notified Body Frontrunners In Race For Designation Under New Regulations
- Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says
- Immuno-Oncology: Unicorns, China And The Perfect Storm
- Unilever Seeks End To Litigation Over St. Ives Scrub, Plaintiffs’ ‘Fake Medical Condition’
- The Emergence Of IO
- Datamonitor Healthcare Strategy: Gene Therapy Commercialization – Opportunities and Barriers
- Adcirca
- Tracleer
- Uptravi
- Letairis
- Adempas
- Opsumit
- Remodulin
- Revatio
- Tyvaso
- Aurora-GT
- INOpulse
- bardoxolone methyl
- esuberaprost
- ralinepag
- Focus More On Patients, Less On Hospitals, Experts Tell Device Companies
- ISO Wants To Tinker With Quality Systems Standard 13485:2016. Let ISO Know What You Think By Nov. 9
- AbbVie Hit Harder By EU Humira Biosimilars Than Projected
- Infant Formula Production Stalls On Reckitt Benckiser’s Latest Stumble
- The Advantages Of Providing Access To Unlicensed Medicines
- Vanda Warning Letter From US FDA Leaves Firm “Puzzled”
- FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence
- The Oncology Burden Of Proof: Learning From The PD-1 Market
- US FDA May Largely Avoid House Democrats’ Investigation Agenda
- Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US
- Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK
- New Year Present For Takeda As Shire Close Nears?
- BSI Is Designated In Netherlands, Giving Clients Go-Ahead To Start Transfer Of Certificates
- P&G Grooming Quits Counting Blades, Innovates In New Directions While Battling DTC Disruptors
- CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests
- First-In-Class Therapies’ Shrinking In-Class Monopolies
- R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking
- Market Access Trends in Europe
- 116th Congress Could Test Cosmetic Industry’s Commitment To Reg Reform, Preemption Viability
- Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US
- Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK
- Strategy At Novartis: Culture Change As The ‘How’ Behind The ‘What’
- Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules
- Epanova
- Evinacumab
- Device Sector Braces For Investigative Stories Critical Of Industry
- Accenture Prescribes A New Data Management Future For Medtechs
- Schleifer, Yancopoulos And The $36 Billion Friendship
- Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies
- Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down
- ISPOR Europe 2018 Whitepaper
- Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change
- Keeping Up With “The Energizer Bunny”: US FDA Commissioner Gottlieb As A Boss
- The Implant Files: EU Blamed For Regulatory Inadequacies The World Over While ‘Wrath’- Behrendt Fumes
- Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures
- Analysts Weigh Up Benefits Of Big Bayer Restructuring
- What’s Under The Iceberg: GE Healthcare’s Deep Dive Look At Future Of Gene Therapy
- Poseida, Legend/Janssen Look To Snag Celgene/ Bluebird’s BCMA Crown
- Commission Addresses Non-EU/EEA Authorities To Set Record Straight On New EU Regs
- Probiotic Safety Latest Target Of Supplement Regulation Critic Cohen
- Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes- Monitoring Market
- Cell And Gene Therapy Logistics Requires Early Planning
- Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry
- Peter Stein Takes Short Path To Director Of US FDA Drug Office
- Gilead Lures Roche Pharma CEO O’Day As CEO; Genentech’s CEO Will Replace Him
- Gene Therapy’s Next Big Challenge: Manufacturing
- US FDA’s Gottlieb Shuts The Door On Exclusivity For ‘Transition’ Biologics
- Four Rules For Being A Consistent US FDA Reviewer From Peter Stein
- EMA Set For More Staff Losses & Activity Cuts Next Year
- FDA Asks Whether Supplement Industry Has Outgrown Regulatory Framework
- Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says
- Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits
- Top 20 Pharma Ranks: As Some Move Up, Others Fall Down
- Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy
- Bayer’s Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth
- EU UDI Deadlines, Documents And Planning: What Does Industry Need To Know?
- ‘Implant Files’: New Device-Failure Database Benefits Companies And Savvy Consumers, But May Befuddle Others, Experts Say
- GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals
- Major Depressive Disorder KOL Interview – UK
- The Case For CAR-T Grows As Responses Hold Up Longer Term
- New Pharma Models for a New Healthcare Era
- PF-06482077
- Pneumovax 23
- Synflorix
- Prevnar 13
- V114
- GSK-3
- 2018 ASH Pulse Survey
- Top 10 Most Read Stories Of 2018
- Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing
- 2018 Biomedtracker Datamonitor Healthcare Post-ASH Report
- Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech
- Germany Begins The Year With Two Possible Rx-To-OTC Switches
- Burt’s Bees Hopes Third Time’s A Charm For Toothpaste, This One With P&G
- Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
- The Next New Thing In FDA Inspections: Poor Root Cause Investigations
- Ischemic Stroke Market and Forecast Analysis 2024
- Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK
- Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest
- Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast
- J&J CEO Sees Victory Ahead On Talc, Growth From Johnson’s Relaunch
- Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses
- Into 2019: Risk, Uncertainty And A Return To Product Focus
- J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA’s Gottlieb
- J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room
- Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage
- J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly
- Fluad QIV
- FluMist QIV
- Flucelvax QIV
- Fluzone High-Dose
- Flublok
- Benefit-Risk Is Front-And-Center In Latest Revision Of International Risk Management Standard ISO 14971
- Notified Bodies And EU Industry Voice Separate, But Aligned Frustrations Over Slow Progress In NB Designations
- MT-2271
- 2018’s Top Biopharma Deal-makers
- The Gene Therapies Are Coming – And So Are New Ways To Pay For Them
- Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances
- Global Biopharma R&D Productivity And Growth Rankings
- Datamonitor Healthcare Multiple Myeloma KOL Interview – UK
- Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US
- Alzheimer’s Disease KOL Interview – UK
- Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin
- Standards, Not Predicates, Emphasized In Finalized Alternative 510(k) Pathway
- EU Beats Predicted Timelines And Appoints First UK Notified Body Against MDR
- What Does 2019 Hold For Biopharma?
- Going ‘Beyond The Pill’ – Sanofi To Partner With Digital Health Start-ups In Europe
- Datamonitor Healthcare HIV KOL Interview – Germany
- Datamonitor Healthcare HIV KOL Interview – UK
- Datamonitor Healthcare HIV KOL Interview – US #1
- Datamonitor Healthcare HIV KOL Interview – US #2
- Alzheimer’s Disease KOL Interview – US, South
- Alzheimer’s Disease KOL Interview – US, Northeast
- US FDA’s Shutdown Offers One Possible Winner
- Yescarta
- umbralisib
- lisocabtagene maraleucel
- Zevalin
- Revlimid
- Kymriah
- Treanda/Bendeka
- Ublituximab
- Imbruvica
- Zydelig
- Rituxan
- Gazyva
- ECLIPSE Psoriasis Pulse Survey
- No More Rebates: HHS Proposed Rule Revises AntiKickback Safe Harbor
- Aliqopa
- Betalutin
- Zanubrutinib
- Copiktra
- Calquence
- Arzerra
- Venclexta
- How To Read The UK’s New Medical Device Regulations: MHRA Explains The Main Points
- Novartis Pharma CEO Sees Zolgensma Supplanting Spinraza
- Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest
- Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany
- Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK
- Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, West Coast
- ‘UKCA Mark’ To Replace CE Marking In UK Now, Or Eventually?
- BSI Touts ‘Very Short’ Waiting Times For Migrating Certificates From UK To Netherlands
- Want To Add A Drug Coating To Your Device? Check FDA’s New Guide
- What GSK’s Immunology Chief Did Next
- Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1
- Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2
- Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK
- Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up
- INCB050465
- Verseon Playing The Long Game To Level Up Drug Discovery
- Surprise As UK Notified Bodies Lose Major Part Of Their UK Role In Devices From March 29
- Never Mind Next-Gen UV Filters; Existing Sunscreen Ingredients’ GRASE Status May Be In Danger
- Modernizing FDA’s Supplement Industry Regulation Mapped Out In Five-Point Plan
- Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer
- Deals Shaping The Medical Industry, February 2019
- From Device Centric To Disease Management: Ascensia Commits To Deeper Role In Diabetes
- Bone Densitometers and Bone Turnover Marker Tests
- Epilepsy KOL Interview – US, West
- Pediatric Epilepsy KOL Interview – US, West
- BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says
- ECHA’s Microplastic Ban Proposal Is ‘Brutally Misinformed’ – Cosmetics Europe
- FDA’s Proposed Sunscreen Rule Could Bring SPFs Back Down To Earth, Deter SPF Fraud Suits
- Annuity Payment Model For Cures May Get Test Drive In Massachusetts
- Mortality Signal For Pfizer’s Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class
- Access Trends in Emerging Markets
- ‘Data Gaps’ Keep 12 Ingredients Off FDA’s Proposed OTC Sunscreen Monograph
- Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
- Reckitt Shaking Up Brain Health Market With Neuriva Dietary Supplement And Mobile App Launch In US
- Alzheimer’s Disease Market and Forecast Analysis 2034
- Invokana
- Jardiance
- Farxiga
- Finerenone
- Cochlear Implants Market
- Eudamed – A Moving Target But On Track For March 2020 Partial Go-Live
- Goodbye To All That: EMA Leaves London After 24 years
- Innovations In Market Access: The Will, But Not The Way?
- Gene Therapy Investment At All Time High, Commercialization Challenges Noted
- AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market
- Novartis Can’t Halt Janssen’s Promo Comparing Their Psoriasis Drugs
- Multiple Myeloma Pricing, Reimbursement, and Access
- Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
- EMA Issues Guidance On Medical Devices That Are Integral To Pharma Products
- Torisel
- abexinostat
- Sutent
- Afinitor
- Votrient
- Bavencio
- Inlyta
- Gottlieb’s Short Tenure Will Be Felt Long After He Leaves US FDA
- Virtual AI Nurses And The Future Of Chronic Disease Management
- CB-839
- Fotivda
- Patient-Specific Drive Takes Ortho Group Corin Into TKR Robotics With Omni Purchase
- Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing
- FDA Determined To Update Cosmetics Regs After Claire’s Refuses To Recall Asbestos-Tainted Makeup
- OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand
- Six Questions For McKinsey Executives On Pharma’s Digital Experience
- How Roche Won The Bidding Battle For Spark
- Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
- The Knowledge Within: An Interview With Merck KGaA’s R&D Chief
- House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform
- Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
- Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
- Cannabis Industry Taking Legal Action Against EU Regulators Over CBD Novel Food Classification
- Sterilization Facility Shutdowns Could Spell Medical Device Shortage; FDA Urges Firms To Assess ‘Downstream Impacts’
- Blood Gas Monitoring Systems
- Psoriasis Pricing, Reimbursement, and Access
- Rapastinel
- Abilify/Abilify Maintena
- Viibryd
- Seroquel/Seroquel XR
- Cymbalta
- Trintellix
- ALKS 5461
- Pristiq
- Latuda
- Lexapro
- Rexulti
- Zulresso
- SAGE-217
- Travivo
- Fetzima
- An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain
- Global Market for Arthroscopy Products and Sports Medicine Implants (2019)
- Gene Therapy Pipeline and Portfolio Analysis
- Global Medical Technology & Device Markets Fact Book 2019
- Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation
- Biosimilar Commercial Strategies and Tactics
- Surgical Heart Valve Management Products
- General and Pelvic Endoscopic Surgery
- Biotech CEOs: Can Scientist-Founders Remain In Charge?
- Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US
- Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France
- Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement
- Key Potential Drug Launches in 2020
- 2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report
- Hearing Aids Market US, 5EU Markets, Japan, and RoW
- Bladder Cancer KOL Interview – US
- 2019 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
- Biosimilars in the US and Europe
- Tivicay
- Triumeq
- Prezista franchise
- Stribild
- Genvoya
- Isentress
- HIV Disease Coverage Forecast and Market Analysis to 2027
- Reyataz
- Atripla
- Complera
- leronlimab
- fostemsavir
- cabotegravir/rilpivirine
- Truvada
- Symtuza
- Odefsey
- Juluca
- Biktarvy
- Dovato
- Global Orthopaedic Markets to 2023
- Specialty Endoscopic Surgery Devices – July 2019
- Interventional Cardiology: Implantable Cardioverter Defibrillators
- Prostate Cancer Diagnostics and Minimally Invasive Treatments Market
- Infection Control and Biosafety Products
- When Deals Go Wrong: Lessons from Failure
- Early Access to Medicines in the US and Europe
- Emricasan
- Firsocostat
- Resmetirom
- Selonsertib
- Tropifexor
- Elafibranor
- Ocaliva
- Aramchol
- VK2809
- Cenicriviroc
- Cilofexor
- 2019 Post-ADA Report
- Novartis’s Zolgensma Loses EU Accelerated Assessment
- Trogarzo
- Descovy
- Delstrigo
- Rheumatoid Arthritis KOL Interview – New Jersey, US
- Rheumatoid Arthritis KOL Interview – New Jersey, US
- Rheumatoid Arthritis KOL Interview – UK
- Rheumatoid Arthritis KOL Interview – California, US
- Why Deals Fail: The Reasons May Be Clinical, Economic Or Strategic
- European Commission Highlights Medtech Notified Bodies Giving It Cause For Concern
- EU Post-Market Clinical Follow Up: What Manufacturers Need To Know
- Commission Looks Set To Expand MDR Extension So Notified Bodies Can Focus On High-Risk Devices
- Two First MDR Certificates Issued – Are Floodgates Open For Mass Certifications?
- FDA’s Quality System Regulation Is Mapped To International Standard ISO 13485 – And Vice Versa – In New Report From AAMI
- EU Post-Market Clinical Follow Up: What Manufacturers Need To Know
- US FDA’s Office Of New Drugs Reorganization Approved, But Not Happening Overnight
- Patients’ Preferred Endpoints May Not Satisfy Regulatory Needs, US FDA Says
- ‘Project Orbis’ Oncology Pilot Eventually Will Target ‘Major Impact’ Applications
- US FDA Looks To Standardize Premarketing Safety Assessments
- Roche: We’ve Abandoned Budgets And It’s Liberated Employees
- Novo Nordisk’s Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed
- Farxiga Data Change Heart Failure Treatment Outlook
- How To Pay For The New Wave Of Gene Therapies
- Two More EU Notified Bodies But Not On Nando Yet
- FDA Announces More Actions On Drug-Coated Devices
- IXICO Targets Go-To Status In Neuro Data Analytics Space
- Orphan Drug Pricing And Reimbursement: Challenges To Patient Access
- GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes
- CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up
- Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’
- L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’
- Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege
- Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark
- Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’
- US Zantac Sales And Distribution Continue As Sanofi Tests For NDMA
- Contamination In Common OTC Antacid Adds To FDA’s API Impurity Concerns
- FDA’s Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident
- US FDA’s Rush Following Novartis’ Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation
- New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development
- Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First
- Commission Would Back Limited Expansion Of Products Covered By MDR Grace Period
- How To Pay For The New Wave Of Gene Therapies
- ESMO Preview: Five Key Oncology Battlegrounds To Watch
- Ranitidine Recalls Begin In Europe As Regulators Take Action
- Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says
- Made In China Gene Therapy A Father’s Quest To Save Son With UltraRare Condition
- Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18
- Made In China Gene Therapy A Father’s Quest To Save Son With UltraRare Condition
- Top 10 Drugs: Weighing Pharma’s Golden Eggs
- Novartis Battens Down Hatches Over Falsified Zolgensma Data
- Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat
- What Does It Take To Launch And Lead An Oncology Biotech Today?
- Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation
- Big Pharma Licensing Trends, 2014–18
- 2018 Completed Clinical Trials: Change Is The New Constant
- Rheumatoid Arthritis Payer Interview – UK
- Rheumatoid Arthritis Payer Interview – Pennsylvania, US
- Global Market for Fracture Fixation Devices
- Identifying High-Growth Medical Technology Markets in SE Asia to 2023
- Vaccines Market Access in Emerging Markets
- US FDA’s Temple on Real-world Evidence: “I Find the Whole Thing Very Frustrating”
- EMA under Pressure again as Staff Losses Worsen
- Countdown To Transition: US FDA Says 91 Drugs Will Become Biologics In March 2020
- Nitrosamine Episode Could Lead To Paradigm Shift In Quality
- Defying FDA: Shanghai Lab Gets Warning Letter But Won’t Relent
- Can Novartis Reclaim Pioneering Role In Transplantation?
- MorphoSys: A European Champion Crossing The Biopharma Rubicon
- Roche: We’ve Abandoned Budgets And It’s Liberated Employees
- The Case For Agile Innovation In Health Care
- GSK’s Hal Barron On R&D Progress At TwoYear Mark
- Testing Ranitidine with Too Much Heat Could Generate NDMA, FDA Say
- Anti-Aging Cosmetics Or Unlawfully Marketed Drugs? Two Federal Court Cases To Watch
- Serious Skin Reactions Reported with Ibuprofen Use in Europe
- A Hangover Is A Disease, German Court Rules
- Schakowsky’s Loaded Cosmetics Bill Described as ‘Floor, Not a Ceiling’ for States to Build On
- Amarin CEO Thero On Gearing Up For Success Ahead Of The Big Vascepa Ad Comm
- Sanofi’s New CEO Paul Hudson Poised To Write The Next Chapter
- Culture Change At GSK: ‘We’re Doing What We Said We’d Do’
- Ranbaxy Brothers Arrested, Downward Spiral Intensifies
- Eight Talking Points from ESMO
- Abbott Launches New App To Keep Heart Failure Patients Out Of The Hospital
- Drug/Device Combinations: Shock For Pharma As It Seeks Notified Body Resources Too
- Six Key New Commission Documents Relating To EU Directives And New Regulations
- US House Panel Approves Medicare Hearing, Dental And Vision Coverage; Senate Bill Introduced
- 86% Rise In GMDN Usage Heralds New Era Of Postmarket Data Analytics
- Nimenrix
- Trumenba
- MenQuadfi
- Menactra
- MenABCW-135Y
- Menveo
- Bexsero
- Nexavar
- Stivarga
- Cyramza
- Opdivo
- tislelizumab
- Lenvima
- Imfinzi
- Cabometyx
- In Vivo’s Quick Guide To Gene Therapy
- Spotlight on Antibody-Drug Conjugates
- One Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis
- Diabetes Management: Insulin Pumps Market (2019)
- Triple-Negative Breast Cancer KOL Interview – US
- Drug Delivery: Inhalation Devices
- Tymlos transdermal patch
- Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration
- Minimally Invasive Heart Valve Repair and Replacement Devices
- 2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report
- Triple-Negative Breast Cancer KOL Interview – UK
- Inclisiran
- Waylivra
- Praluent
- Juxtapid
- Vascepa
- Repatha
- Bempedoic Acid Franchise
- The Real Value of Medtech Markets: The impact of currency movements
- Drug Delivery: Injection Devices
- Diabetes Management: Blood Glucose Monitoring Devices Market
- Human Papillomavirus (HPV) KOL Interview – US, Midwest
- Human Papillomavirus (HPV) KOL Interview – Italy
- Type 1 Diabetes KOL Interview – US, Midwest
- Type 1 Diabetes KOL Interview – UK
- 2019 ASH Pulse Survey
- Market Spotlight: Myelofibrosis
- Company Analysis: Merck KGaA
- Company Analysis: Otsuka
- Transcatheter Embolization and Occlusion Devices
- Abraxane
- Halaven
- Keytruda
- Talzenna
- Avastin
- Tecentriq
- Lynparza
- Veliparib
- Sacituzumab govitecan
- Ipatasertib
- Onzeald
- Enhertu
- capivasertib
- balixafortide
- adagloxad simolenin
- Multiple Sclerosis (MS) KOL Interview – US, Midwest
- Multiple Sclerosis (MS) KOL Interview – UK, Southwest
- Multiple Sclerosis (MS) KOL Interview – UK, London
- HER2+ Breast Cancer KOL Interview – US, West Coast
- HER2+ Breast Cancer KOL Interview – UK
- Orthobiologics for Bone Repair and Regeneration
- Digital Health: Diabetes Apps and Virtual Coaching
- Hemophilia KOL Interview – US, Southeast
- Hemophilia KOL Interview – UK
- Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK
- Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US, East Coast
- Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast
- Acute Myeloid Leukemia (AML) KOL Interview – UK
- Ovarian Cancer KOL Interview – US, East Coast
- Ovarian Cancer KOL Interview – UK
- Head and Neck Cancer KOL Interview – UK
- Head and Neck Cancer KOL Interview – US, Southeast
- Drug Delivery: Transdermal Devices
- Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market
- Renal Cell Carcinoma KOL Interview – US, Southeast
- Renal Cell Carcinoma KOL Interview – UK
- Multiple Myeloma KOL Interview – UK
- Multiple Myeloma KOL Interview – US
- Spinal Motion Preservation Devices Market
- Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices
- Anemia in Chronic Kidney Disease KOL Interview – US, East Coast
- Anemia in Chronic Kidney Disease KOL Interview – US, West Coast
- Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest
- Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Midwest
- Biomedtracker / Meddevicetracker Q3 2020 Outlook Report
- Company Analysis : AbbVie
- Company Analysis: Boehringer Ingelheim
- Key Potential Drug Launches in 2021
- Neuromodulation: Spinal Cord Stimulation Devices Market
- Gastric Cancer KOL Interview – US
- Drug Delivery: Infusion Devices – August 2020
- Market Spotlight: Migraine
- Market Spotlight: Atopic Dermatitis
- Spinal Fusion: Implanted Instrumentation
- Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast
- Company Analysis: Pfizer
- Market Spotlight: Psoriatic Arthritis
- Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators
- Molecular Diagnostics Market
- Chronic Lymphocytic Leukemia (CLL) KOL Interview – US
- 2020 Post-ESMO Report
- Market Spotlight: Glioblastoma
- Biomedtracker Q4 2020 Outlook Report
- Hip Replacement Implants Market
- Colorectal Cancer KOL Interview – US
- Neurointervention: Mechanical Thrombectomy Devices Market
- Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines
- Melanoma KOL Interview – US
- Wound Care: Advanced Dressings and Closure Products
- Prostate Cancer KOL Interview – US
- Knee Replacement Implants Market
- Trends: Hot Topic Catalyst
- Respiratory Care: Noninvasive Ventilation and Airway Management Products
- Extremity Replacement Implants
- Diabetes Management: Insulin Pumps Market (2020)
- Company Analysis: GlaxoSmithKline
- Company Analysis: Incyte
- 2021 J.P. Morgan Healthcare Conference Review
- Company Analysis: United Therapeutics
- Company Analysis: UCB
- Company Analysis: Seagen
- Company Analysis: Ionis Pharmaceuticals
- Company Analysis: Alexion
- Company Analysis: Regeneron
- Company Analysis: Biogen
- Company Analysis: BioMarin
- Company Analysis: AbbVie
- Company Analysis: AstraZeneca
- Company Analysis: Bayer
- Company Analysis: Bristol-Myers Squibb
- Company Analysis: Eli Lilly
- Company Analysis: Merck & Co
- Company Analysis: Novartis
- Company Analysis: Novo Nordisk
- Company Analysis: Roche
- Company Analysis: Sanofi
- Company Analysis: Teva
- Company Analysis: Gilead
- Company Analysis: Lundbeck
- Company Analysis: Vertex
- Company Analysis: Johnson & Johnson
- Company Analysis: Amgen
- Company Analysis: Kyowa Kirin
- Company Analysis: Astellas
- Company Analysis: Daiichi Sankyo
- Company Analysis: Sumitomo Dainippon
- Company Analysis: Eisai
- Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038
- Company Analysis: Mitsubishi Tanabe
- Company Analysis: Ono Pharmaceutical
- Company Analysis: Takeda
- Company Analysis: Shionogi
- Biomedtracker Early 2021 Outlook Report
- Inflammatory Bowel Disease (IBD) KOL Interview – US
- Ulcerative Colitis (UC) KOL Interview – UK
- Depression KOL Interview – US #1
- Depression KOL Interview – US #2
- Arthroscopy Products and Sports Medicine Fixation Implants (2021)
- Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems
- Diabetes Management: Blood Glucose Monitoring Devices Market (2021)
- Disease Analysis: Chronic Heart Failure
- Biomedtracker / Meddevicetracker Q2 2021 Outlook Report
- Schizophrenia and Bipolar Disorder KOL Interview – Germany
- Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast
- Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast
- Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast
- Schizophrenia and Bipolar Disorder Payer Interview – US, South
- Cardiac Ablation Catheters Market
- Disease Analysis: Pneumococcal Vaccines
- Robotically Assisted Surgical Devices Market
- Q3 2021 Outlook Report
- Market Spotlight: Sickle Cell Anemia
- Follicular Lymphoma KOL Interview – UK
- Surgical Heart Valve Repair and Replacement Devices
- Point of Care Diagnostics
- Disease Analysis: NHL: Follicular Lymphoma
- Follicular Lymphoma KOL Interview – US
- Disease Analysis: Ovarian Cancer
- Disease Analysis: Gastric Cancer
- Fracture Fixation Devices Market
- Chronic Myeloid Leukemia (CML) KOL Interview – UK
- Chronic Myeloid Leukemia (CML) KOL Interview – US, Midwest
- HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1
- HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2
- Market Spotlight: Gout
- Disease Analysis: Cystic Fibrosis
- Disease Analysis: Bipolar Disorder
- Market Spotlight: Glaucoma
- Transcatheter Heart Valve Repair and Replacement Devices
- Disease Analysis: Prostate Cancer
- Disease Analysis: Alzheimer’s Disease
- Market Spotlight: Erectile Dysfunction
- Interventional Cardiology: Carotid Artery Stents and Embolic Protection Systems
- Disease Analysis Atopic Dermatitis
- Disease Analysis: Melanoma
- Disease Analysis: Bladder Cancer
- Market Spotlight: Renal Disease
- Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)
- Market Spotlight: Basal Cell Carcinoma
- Market Spotlight: Fibromyalgia
- Market Spotlight: Cervical Cancer
- Market Spotlight: Esophageal Cancer
- Market Spotlight: Duchenne Muscular Dystrophy (DMD)
- Market Spotlight: Insomnia
- Market Spotlight: Axial Spondyloarthritis (axSpA)
- Market Spotlight: Sjögren’s Syndrome
- Disease Analysis: Anemia in Chronic Kidney Disease
- Market Spotlight: Polycystic Ovary Syndrome (PCOS)
- Market Spotlight: Celiac Disease
- Disease Analysis: Dengue Vaccines
- Market Spotlight: Hereditary Angioedema
- Disease Analysis: Migraine
- Market Spotlight: Thyroid Cancer
- Disease Analysis: Ulcerative Colitis
- Disease Analysis: Multiple Sclerosis
- Disease Analysis: Crohn’s Disease
- Disease Analysis: Hepatitis C
- Disease Analysis: Seasonal Influenza Vaccines
- Liquid Biopsy Oncology Market
- Disease Analysis: Acute Myeloid Leukemia (AML)
- Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)
- Market Spotlight: Chemotherapy-Induced Anemia
- Market Spotlight: Acne
- Disease Analysis: Renal Cell Carcinoma (RCC)
- Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)
- Market Spotlight: Irritable Bowel Syndrome (IBS)
- Market Spotlight: Mantle Cell Lymphoma
- Disease Analysis: Depression
- Disease Analysis: Schizophrenia
- Disease Analysis: Type 2 Diabetes
- Disease Analysis: Psoriatic Arthritis
- Market Spotlight: Atrial Fibrillation
- Market Spotlight: Dry Eye Disease
- Market Spotlight: Uterine Fibroids
- Market Spotlight: Eating Disorders
- Disease Analysis: Meningococcal Vaccines
- Market Spotlight: Lysosomal Storage Disorders
- Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)
- Disease Analysis: Parkinson’s Disease
- Market Spotlight: Uterine Cancer
- Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)
- Disease Analysis: HIV Treatment
- Disease Analysis: COVID-19 Treatment
- Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
- Disease Analysis: COVID-19 Prevention
- Market Spotlight: Systemic Lupus Erythematosus (SLE)
- Market Spotlight: Amyloidosis
- Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration – 2021
- Market Spotlight: Glioblastoma (GBM)
- Disease Analysis: Hepatocellular Carcinoma (HCC)
- Market Spotlight: Gastrointestinal Stromal Tumor (GIST)
- Disease Analysis: Hemophilia
- Market Spotlight: Waldenström Macroglobulinemia (WM)
- Market Spotlight: Systemic Hypertension
- Disease Analysis: Multiple Myeloma
- Market Spotlight: Benign Prostatic Hyperplasia (BPH)
- Market Spotlight: Biliary Tract Cancer
- Market Spotlight: Neuroendocrine tumors (NET)
- Market Spotlight: Sarcoma
- Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)
- Interventional Cardiology: Implantable Pacemaker Products
- Disease Analysis: Human Papillomavirus (HPV) Vaccines
- Disease Analysis: Type 1 Diabetes
- Market Spotlight: Hodgkin’s Lymphoma
- Market Spotlight: Primary Sclerosing Cholangitis (PSC)
- Market Spotlight: Overactive Bladder
- Market Spotlight: Huntington’s Disease
- Disease Analysis: Colorectal Cancer
- Disease Analysis: Diabetic Nephropathy
- Market Spotlight: Tumor Lysis Syndrome (TLS)
- Disease Analysis: Head and Neck Cancer
- Disease Analysis: Epilepsy
- Market Spotlight: Mesothelioma
- Market Spotlight: Coronary Artery Disease
- Disease Analysis: Pulmonary Hypertension
- Disease Analysis: HER2+ Breast Cancer
- Market Spotlight: Tuberculosis (TB)
- Market Spotlight: Ischemic Stroke
- Market Spotlight: Venous Thromboembolism (VTE)
- Market Spotlight: Cold Agglutinin Disease
- Market Spotlight: Amyotrophic Lateral Sclerosis (ALS)
- Market Spotlight: Opioid-Induced Constipation
- Market Spotlight: Osteoarthritis and Osteoarthritis Pain
- Market Spotlight: Neuropathic Pain
- Market Spotlight: Cachexia
- Market Spotlight: Small-Cell Lung Cancer (SCLC)
- Market Spotlight: Pancreatic Cancer
- Market Spotlight: Norovirus
- Market Spotlight: Thyroid Eye Disease (TED)
- Market Spotlight: Myelofibrosis (MF)
- Market Spotlight: Hypogonadism
- Market Spotlight: Acute Decompensated Heart Failure (ADHF)
- Market Spotlight: Hidradenitis Suppurativa
- Market Spotlight: Myelodysplastic Syndrome (MDS)
- Market Spotlight: Fragile X Syndrome
- Market Spotlight: Zika virus
- Market Spotlight: Endometriosis
- Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)
- Market Spotlight: Obesity
- Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
- Market Spotlight: Hepatitis B
- Disease Analysis: Psoriasis
- Ophthalmic Surgical Products Market
- Disease Analysis: Dyslipidemia
- Digital Health Technology and Regulatory Overview
- Disease Analysis: Asthma
- Drug Delivery: Inhalation Devices
- Disease Analysis: Wet Age-Related Macular Degeneration
- Interventional Cardiology: Implantable Cardioverter Defibrillators
- Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems
- Disease Analysis: HR+/HER2- Breast Cancer
- Disease Analysis: Triple-Negative Breast Cancer
- Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention
- Disease Analysis: Osteoporosis
- Disease Analysis: Rheumatoid Arthritis
- Chronic Lymphocytic Leukemia (CLL)
- Disease Analysis: Chronic Myeloid Leukemia (CML)
Product categories
- A
- Allergy
- Anemias
- Autoimmune / Immunology
- B-C
- Bacterial infections
- Big Pharma
- Bleeding disorders
- Bleeding disorders
- Brain Cancer
- Breast and gynecological cancer
- Breast and gynecological cancer
- Business Development
- Business Management
- Business Process
- Cardiovascular
- Cardiovascular and Metabolic
- Cardiovascular and Metabolic
- Central Nervous System
- Central Nervous System
- Cerebrovascular diseases
- Clinical Trials
- Commercial Strategy
- Company analysis
- Company analysis
- Compliance & Risk
- Cybersecurity
- D-F
- Dealmaking and R&D
- Dermatology
- Dermatology
- Diabetes
- Diabetes and diabetic complications
- Diagnostics
- Digital Health
- Digital patient management
- Digital policy & regulation
- Disease analysis
- Disease analysis
- Drug analysis
- Drug Analysis
- Drug analysis
- Emerging Pharma
- Endocrine
- ENT / Dental
- Finance & Pricing
- G-L
- Gastroenterology
- Gastroenterology
- Gastroenterology
- Gastrointestinal cancer
- Gastrointestinal cancer
- Head and Neck Cancer
- Hearing
- Heart failure
- Hematology
- Hot Topics
- Hot Topics
- Hypertension
- ICT and Health
- Immunology and Inflammation
- Immunology and Inflammation
- Infectious Diseases
- Infectious Diseases
- Infectious Diseases
- Japan Pharma
- KOL Insight
- Leadership
- Legislation Regulation & Policy
- Leukemia
- Leukemia
- Lung Cancer
- Lung Cancer
- Lymphoma
- Lymphoma
- M&A Analysis
- M-O
- Manufacturing
- Market Access
- Market Access
- Market Intelligence
- Market Spotlight
- Medical
- MedTech analysis
- MedTech analysis
- MedTech analysis
- Medtech Markets
- Men's Health
- Mens Health
- Metabolic
- Mid Pharma
- Neurology
- Neurology
- Neurology
- Not Specified
- Obstetrics / Gynecology
- Oncology
- Oncology
- Oncology
- Ophthalmology
- Ophthalmology
- Opinion & analysis
- Orthopedics
- Osteoporosis
- Other
- Other hematological cancers
- Other Hematological Cancers
- Other metabolic diseases
- Other Solid Cancers
- Outsourcing
- P-R
- Pain
- Pain
- Pharmaceutical Device
- Pharmaceutical Research
- Pricing & Reimbursement
- Psychiatry
- Psychiatry
- Psychiatry
- R&D
- Regulatory & Therapeutic Area
- Renal
- Report library
- Respiratory
- Respiratory
- Rheumatology
- Rheumatology
- S-T
- Skin Cancer
- Skin cancer
- Strategy & Innovation
- Strategy analysis
- Strategy analysis
- Strategy analysis
- Tech & Pharma
- Thrombosis
- Trends
- U-Z
- Urological cancer
- Urological cancer
- Urology
- Vaccines
- Viral infections
- Viral infections
- Women's Health
Product tags
Product License
Sign up to the